Speclipse Makes Debut at IMCAS Asia, Accelerates Global Market Expansion

Speclipse, a company specializing in laser and AI-based skin treatment and skin cancer diagnostics, announced on June 10 that it participated in the International Master Course on Aging Science (IMCAS) Asia 2025, held in Bangkok, Thailand from June 6 to 8, establishing a foothold for expanding into the Asian market.

At the event, Speclipse operated live demonstrations at its booth and introduced its laser dermatology and treatment devices, including "PICO-K" and "BELLUS-Q." The company also supported a local physician's academic presentation titled "Beyond pigment removal: The next generation of Picosecond laser in skin rejuvenation." According to the company, these products attracted significant interest from medical professionals and buyers visiting the booth.

During the event, Speclipse held discussions to expand supply with its local partner in Thailand, while also focusing on strengthening partnerships with buyers from Malaysia and Singapore that were identified during its participation in "KIMES 2025" in March. The company is accelerating its global market expansion by broadening its network in emerging markets such as India, Indonesia, and the Philippines.

The flagship product, PICO-K, recorded sales of over 100 units in Taiwan in its first year of launch in 2024, responding to high demand for aesthetic medical equipment. The company has been increasing its market share through marketing activities such as launch events and TV commercials featuring well-known local celebrities. In the United States, Speclipse is preparing for FDA approval in early 2026, working with local partners to select key doctors and publish academic papers, while also expediting pre-approval procedures such as quality inspections.

Hong Junghwan, CEO of Speclipse, stated, "Through our first participation in IMCAS Asia, we were able to enhance both brand awareness and credibility. We also plan to participate in 'IMCAS World 2026' next year, which will be held after FDA approval." He added, "With the recent acquisition of Russian regulatory approval in addition to European CE certification, we will implement a multifaceted export strategy covering both the CIS region and the European market." He further commented, "We will make 2025 a strategic starting point for global expansion and accelerate our entry into new markets."

Speclipse's PICO-K is a cosmetic and therapeutic medical device that effectively improves pigmentation disorders and promotes skin rejuvenation through a 300-picosecond high-power laser, featuring precise and rapid energy delivery. BELLUS-Q supports a high-power 1.5J nanosecond laser and various pulse modes, enabling customized treatments according to pigment type and lesion depth.

The company is aiming to go public in 2026, challenging for a technology-special listing in the second half of this year. Korea Investment & Securities has been selected as the lead underwriter.